This podcast highlights key stories from the drug discovery world, focusing on haematology. Topics include real-world evidence on CAR-T therapies in blood cancers, new data for myeloma and lymphoma treatments, clinical trial results for lymphoma and pediatric acute lymphoblastic leukemia therapies, and a collaboration for manufacturing lentiviral vectors for CAR-P-A-L-L clinical trial.
Bristol Myers Squibb obtains approval in Japan for a bechma as a third-line therapy for relapsed or refractory multiple myeloma, demonstrating its effectiveness in addressing unmet needs of multiple myeloma patients.
Real-world evidence from the French Descartes registry suggests the potential of axocaptogene silolucile as an alternative treatment option for relapsed large B cell lymphoma patients, providing valuable insights into the use of CARTA cell therapies for patients who do not respond to first-line treatment or experience early relapse.
Deep dives
Bristol Myers Squibb receives approval in Japan for bechma in multiple myeloma treatment
Bristol Myers Squibb has obtained manufacturing and marketing approval in Japan for a bechma, Ida Cabbed Jean Vichlucil, as a third-line therapy for relapsed or refractory multiple myeloma. The approval is based on data from the Phase 3 CAR MMA-3 study, showing that a bechma demonstrated a 51% lower risk of disease progression or death compared to the standard regimen. The overall response rate was 71.3% in the a bechma arm, highlighting its effectiveness in addressing the unmet needs of multiple myeloma patients.
Real-world evidence shows positive outcomes in large B cell lymphoma with axocaptogene silolucile
Real-world evidence from the French Descartes registry reveals that axocaptogene silolucile, CARTA, demonstrated an overall response rate of 76.9% and a complete response rate of 57.7% in large B cell lymphoma patients. This study provides valuable insight into the use of CARTA cell therapies, particularly for patients who do not respond to first-line treatment or experience early relapse. The results suggest the potential of axocaptogene silolucile as an alternative treatment option for relapsed large B cell lymphoma.
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of CAR-T therapies in blood cancers and new data for myeloma and lymphoma treatments.